As of 3:59pm ET
| +0.0145 / +2.46%|
The 1 analysts offering 12-month price forecasts for Peregrine Pharmaceuticals Inc have a median target of 2.00, with a high estimate of 2.00 and a low estimate of 2.00. The median estimate represents a +230.80% increase from the last price of 0.60.
The current consensus among 1 polled investment analysts is to Buy stock in Peregrine Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.